SEC Comment Letter 0000000000-24-003611 to LENZ Therapeutics, Inc. (LENZ)
LENZ Therapeutics, Inc.
Date: April 3, 2024 · CIK: 0001815776 · Accession: 0000000000-24-003611
AI Filing Summary & Sentiment
File numbers found in text: 333-278393
Letter
United States securities and exchange commission logo April 3, 2024 Evert Schimmelpennink President and Chief Executive Officer LENZ Therapeutics, Inc. 445 Marine View Ave., Ste. #320 Del Mar, California 92014 Re:LENZ Therapeutics, Inc. Registration Statement on Form S-1 Filed March 29, 2024 File No. 333-278393 Dear Evert Schimmelpennink: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at 202-551-6761 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Ben Capps
Show Raw Text
United States securities and exchange commission logo
April 3, 2024
Evert Schimmelpennink
President and Chief Executive Officer
LENZ Therapeutics, Inc.
445 Marine View Ave., Ste. #320
Del Mar, California 92014
Re:LENZ Therapeutics, Inc.
Registration Statement on Form S-1
Filed March 29, 2024
File No. 333-278393
Dear Evert Schimmelpennink:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Chris Edwards at 202-551-6761 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Ben Capps